RT Journal Article
SR Electronic
T1 Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1607
OP 1614
DO 10.21873/anticanres.14922
VO 41
IS 3
A1 ISHIYAMA, YUDAI
A1 KONDO, TSUNENORI
A1 NEMOTO, YUKI
A1 KOBARI, YUKI
A1 ISHIHARA, HIROKI
A1 TACHIBANA, HIDEKAZU
A1 YOSHIDA, KAZUHIKO
A1 HASHIMOTO, YASUNOBU
A1 TAKAGI, TOSHIO
A1 IIZUKA, JUNPEI
A1 TANABE, KAZUNARI
YR 2021
UL http://ar.iiarjournals.org/content/41/3/1607.abstract
AB Background/Aim: We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab. Patients and Methods: Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated. Results: In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group. Conclusion: PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab.